With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts.
On May 18, H.C. Wainwright analyst Swayampakula Ramakanth assumed coverage of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) with a Buy rating and a $4 price target. According to the analyst, the company’s lead therapy, LYMPHIR, has already received approval for the treatment of relapsed or refractory Stage I-III cutaneous T-cell lymphoma. H.C. Wainwright noted that early commercial launch metrics appear encouraging, highlighting nearly full commercial insurance coverage, strong formulary positioning across target healthcare accounts, and the company’s initial international shipment into Europe through a regional distribution partner. The firm believes these developments support the broader commercialization outlook for LYMPHIR as Citius continues expanding market access.
Previously, on April 29, Citius Oncology, the majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), announced the first shipment of LYMPHIR into Europe through one of its regional distribution partners. The therapy will initially be provided to eligible patients through Named Patient Programs in accordance with local country regulations. Management described the European launch initiative as an important strategic milestone in expanding international access for patients with limited treatment options while maintaining a disciplined commercial rollout strategy. LYMPHIR previously received approval from the U.S. Food and Drug Administration in August 2024 for adult patients with relapsed or refractory cutaneous T-cell lymphoma following at least one prior systemic therapy and was commercially launched in the United States in December 2025.
Founded in 2007 and headquartered in Cranford, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is a late-stage biopharmaceutical company focused on developing and commercializing critical care and oncology therapies. The company’s pipeline includes treatments targeting unmet medical needs in oncology, infectious disease management, and supportive care markets.
While we acknowledge the risk and potential of CTXR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CTXR and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 7 Best Heavy Equipment Stocks to Buy as Backlogs Hit Records and 9 Best Natural Gas Stocks to Buy for Transitional Power.
Disclosure: None. Follow Insider Monkey on Google News.
